Biosensors makes Singapore public debut

18 Jan 2013

Singapore medical technology company Biosensors International made its debut in the public bond market at the start of the week, raising S$300m ($244.9m).

It sold the deal through its subsidiary Biosensors Investment, after picking Credit Suisse and Standard Chartered as bookrunners. The two banks drummed up enough demand to close a S$300m 4.875% January 2019 bond at par, an impressive outcome for a debut issuer in Singapore dollars, said a banker ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Oops, something went wrong

We're sorry but at the moment we can't load this data